About This Video
This video is
Celsion Corporation (NASDAQ:CLSN) announced today initiation of a nationwide enrollment program in its pivotal Phase I/II DIGNITY clinical trial evaluating the use of ThermoDox® in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer. In early studies, conducted at Duke University Medical Center, investigators report that ThermoDox® has demonstrated significant promise in treating this highly aggressive disease.
To view Multimedia News Release, go to
http://www2.prnewswire.com/mnr/celsion/39944/
This website uses Adobe® Flash™ Player 9
Download Flash Now
If you are using Internet Explorer, you will need to restart your browser
after installing Flash.
Adobe and Flash are registered trademarks of Adobe Systems incorporated.
All rights reserved.
